INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (18201, 21983, 'Pregabalin', 'Substance-Related Disorders', 'Anxiolytic, sedative, and hypnotic agents have the potential to cause dependence and abuse.  Tolerance as well as physical and psychological dependence can develop, particularly after prolonged use of excessive dosages, and abrupt cessation and/or a reduction in dosage may precipitate withdrawal symptoms.  In patients who have developed tolerance, overdosage can still produce respiratory depression and death.  Therapy with anxiolytic, sedative, and hypnotic agents should be administered cautiously and for as brief a period as possible.  Addiction-prone individuals, such as those with a history of alcohol or substance abuse, should be under careful surveillance or medical supervision when treated with these agents.  In addition, it may be prudent to refrain from dispensing large quantities of medication to such patients.  After prolonged use or if dependency is suspected, withdrawal of medication should be undertaken gradually using a dosage-tapering schedule.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (18202, 22139, 'Pregabalin', 'Substance-Related Disorders', 'Anxiolytic, sedative, and hypnotic agents have the potential to cause dependence and abuse.  Tolerance as well as physical and psychological dependence can develop, particularly after prolonged use of excessive dosages, and abrupt cessation and/or a reduction in dosage may precipitate withdrawal symptoms.  In patients who have developed tolerance, overdosage can still produce respiratory depression and death.  Therapy with anxiolytic, sedative, and hypnotic agents should be administered cautiously and for as brief a period as possible.  Addiction-prone individuals, such as those with a history of alcohol or substance abuse, should be under careful surveillance or medical supervision when treated with these agents.  In addition, it may be prudent to refrain from dispensing large quantities of medication to such patients.  After prolonged use or if dependency is suspected, withdrawal of medication should be undertaken gradually using a dosage-tapering schedule.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (18203, 22143, 'Pregabalin', 'Substance-Related Disorders', 'Anxiolytic, sedative, and hypnotic agents have the potential to cause dependence and abuse.  Tolerance as well as physical and psychological dependence can develop, particularly after prolonged use of excessive dosages, and abrupt cessation and/or a reduction in dosage may precipitate withdrawal symptoms.  In patients who have developed tolerance, overdosage can still produce respiratory depression and death.  Therapy with anxiolytic, sedative, and hypnotic agents should be administered cautiously and for as brief a period as possible.  Addiction-prone individuals, such as those with a history of alcohol or substance abuse, should be under careful surveillance or medical supervision when treated with these agents.  In addition, it may be prudent to refrain from dispensing large quantities of medication to such patients.  After prolonged use or if dependency is suspected, withdrawal of medication should be undertaken gradually using a dosage-tapering schedule.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (18204, 22145, 'Pregabalin', 'Substance-Related Disorders', 'Anxiolytic, sedative, and hypnotic agents have the potential to cause dependence and abuse.  Tolerance as well as physical and psychological dependence can develop, particularly after prolonged use of excessive dosages, and abrupt cessation and/or a reduction in dosage may precipitate withdrawal symptoms.  In patients who have developed tolerance, overdosage can still produce respiratory depression and death.  Therapy with anxiolytic, sedative, and hypnotic agents should be administered cautiously and for as brief a period as possible.  Addiction-prone individuals, such as those with a history of alcohol or substance abuse, should be under careful surveillance or medical supervision when treated with these agents.  In addition, it may be prudent to refrain from dispensing large quantities of medication to such patients.  After prolonged use or if dependency is suspected, withdrawal of medication should be undertaken gradually using a dosage-tapering schedule.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (18205, 22146, 'Pregabalin', 'Substance-Related Disorders', 'Anxiolytic, sedative, and hypnotic agents have the potential to cause dependence and abuse.  Tolerance as well as physical and psychological dependence can develop, particularly after prolonged use of excessive dosages, and abrupt cessation and/or a reduction in dosage may precipitate withdrawal symptoms.  In patients who have developed tolerance, overdosage can still produce respiratory depression and death.  Therapy with anxiolytic, sedative, and hypnotic agents should be administered cautiously and for as brief a period as possible.  Addiction-prone individuals, such as those with a history of alcohol or substance abuse, should be under careful surveillance or medical supervision when treated with these agents.  In addition, it may be prudent to refrain from dispensing large quantities of medication to such patients.  After prolonged use or if dependency is suspected, withdrawal of medication should be undertaken gradually using a dosage-tapering schedule.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (18206, 22147, 'Pregabalin', 'Substance-Related Disorders', 'Anxiolytic, sedative, and hypnotic agents have the potential to cause dependence and abuse.  Tolerance as well as physical and psychological dependence can develop, particularly after prolonged use of excessive dosages, and abrupt cessation and/or a reduction in dosage may precipitate withdrawal symptoms.  In patients who have developed tolerance, overdosage can still produce respiratory depression and death.  Therapy with anxiolytic, sedative, and hypnotic agents should be administered cautiously and for as brief a period as possible.  Addiction-prone individuals, such as those with a history of alcohol or substance abuse, should be under careful surveillance or medical supervision when treated with these agents.  In addition, it may be prudent to refrain from dispensing large quantities of medication to such patients.  After prolonged use or if dependency is suspected, withdrawal of medication should be undertaken gradually using a dosage-tapering schedule.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (18207, 22148, 'Pregabalin', 'Substance-Related Disorders', 'Anxiolytic, sedative, and hypnotic agents have the potential to cause dependence and abuse.  Tolerance as well as physical and psychological dependence can develop, particularly after prolonged use of excessive dosages, and abrupt cessation and/or a reduction in dosage may precipitate withdrawal symptoms.  In patients who have developed tolerance, overdosage can still produce respiratory depression and death.  Therapy with anxiolytic, sedative, and hypnotic agents should be administered cautiously and for as brief a period as possible.  Addiction-prone individuals, such as those with a history of alcohol or substance abuse, should be under careful surveillance or medical supervision when treated with these agents.  In addition, it may be prudent to refrain from dispensing large quantities of medication to such patients.  After prolonged use or if dependency is suspected, withdrawal of medication should be undertaken gradually using a dosage-tapering schedule.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (18208, 22150, 'Pregabalin', 'Substance-Related Disorders', 'Anxiolytic, sedative, and hypnotic agents have the potential to cause dependence and abuse.  Tolerance as well as physical and psychological dependence can develop, particularly after prolonged use of excessive dosages, and abrupt cessation and/or a reduction in dosage may precipitate withdrawal symptoms.  In patients who have developed tolerance, overdosage can still produce respiratory depression and death.  Therapy with anxiolytic, sedative, and hypnotic agents should be administered cautiously and for as brief a period as possible.  Addiction-prone individuals, such as those with a history of alcohol or substance abuse, should be under careful surveillance or medical supervision when treated with these agents.  In addition, it may be prudent to refrain from dispensing large quantities of medication to such patients.  After prolonged use or if dependency is suspected, withdrawal of medication should be undertaken gradually using a dosage-tapering schedule.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (18209, 22154, 'Pregabalin', 'Substance-Related Disorders', 'Anxiolytic, sedative, and hypnotic agents have the potential to cause dependence and abuse.  Tolerance as well as physical and psychological dependence can develop, particularly after prolonged use of excessive dosages, and abrupt cessation and/or a reduction in dosage may precipitate withdrawal symptoms.  In patients who have developed tolerance, overdosage can still produce respiratory depression and death.  Therapy with anxiolytic, sedative, and hypnotic agents should be administered cautiously and for as brief a period as possible.  Addiction-prone individuals, such as those with a history of alcohol or substance abuse, should be under careful surveillance or medical supervision when treated with these agents.  In addition, it may be prudent to refrain from dispensing large quantities of medication to such patients.  After prolonged use or if dependency is suspected, withdrawal of medication should be undertaken gradually using a dosage-tapering schedule.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (18210, 23147, 'Pregabalin', 'Substance-Related Disorders', 'Anxiolytic, sedative, and hypnotic agents have the potential to cause dependence and abuse.  Tolerance as well as physical and psychological dependence can develop, particularly after prolonged use of excessive dosages, and abrupt cessation and/or a reduction in dosage may precipitate withdrawal symptoms.  In patients who have developed tolerance, overdosage can still produce respiratory depression and death.  Therapy with anxiolytic, sedative, and hypnotic agents should be administered cautiously and for as brief a period as possible.  Addiction-prone individuals, such as those with a history of alcohol or substance abuse, should be under careful surveillance or medical supervision when treated with these agents.  In addition, it may be prudent to refrain from dispensing large quantities of medication to such patients.  After prolonged use or if dependency is suspected, withdrawal of medication should be undertaken gradually using a dosage-tapering schedule.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (18211, 23148, 'Pregabalin', 'Substance-Related Disorders', 'Anxiolytic, sedative, and hypnotic agents have the potential to cause dependence and abuse.  Tolerance as well as physical and psychological dependence can develop, particularly after prolonged use of excessive dosages, and abrupt cessation and/or a reduction in dosage may precipitate withdrawal symptoms.  In patients who have developed tolerance, overdosage can still produce respiratory depression and death.  Therapy with anxiolytic, sedative, and hypnotic agents should be administered cautiously and for as brief a period as possible.  Addiction-prone individuals, such as those with a history of alcohol or substance abuse, should be under careful surveillance or medical supervision when treated with these agents.  In addition, it may be prudent to refrain from dispensing large quantities of medication to such patients.  After prolonged use or if dependency is suspected, withdrawal of medication should be undertaken gradually using a dosage-tapering schedule.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (18212, 23429, 'Pregabalin', 'Substance-Related Disorders', 'Anxiolytic, sedative, and hypnotic agents have the potential to cause dependence and abuse.  Tolerance as well as physical and psychological dependence can develop, particularly after prolonged use of excessive dosages, and abrupt cessation and/or a reduction in dosage may precipitate withdrawal symptoms.  In patients who have developed tolerance, overdosage can still produce respiratory depression and death.  Therapy with anxiolytic, sedative, and hypnotic agents should be administered cautiously and for as brief a period as possible.  Addiction-prone individuals, such as those with a history of alcohol or substance abuse, should be under careful surveillance or medical supervision when treated with these agents.  In addition, it may be prudent to refrain from dispensing large quantities of medication to such patients.  After prolonged use or if dependency is suspected, withdrawal of medication should be undertaken gradually using a dosage-tapering schedule.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (18213, 23431, 'Pregabalin', 'Substance-Related Disorders', 'Anxiolytic, sedative, and hypnotic agents have the potential to cause dependence and abuse.  Tolerance as well as physical and psychological dependence can develop, particularly after prolonged use of excessive dosages, and abrupt cessation and/or a reduction in dosage may precipitate withdrawal symptoms.  In patients who have developed tolerance, overdosage can still produce respiratory depression and death.  Therapy with anxiolytic, sedative, and hypnotic agents should be administered cautiously and for as brief a period as possible.  Addiction-prone individuals, such as those with a history of alcohol or substance abuse, should be under careful surveillance or medical supervision when treated with these agents.  In addition, it may be prudent to refrain from dispensing large quantities of medication to such patients.  After prolonged use or if dependency is suspected, withdrawal of medication should be undertaken gradually using a dosage-tapering schedule.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (18214, 23432, 'Pregabalin', 'Substance-Related Disorders', 'Anxiolytic, sedative, and hypnotic agents have the potential to cause dependence and abuse.  Tolerance as well as physical and psychological dependence can develop, particularly after prolonged use of excessive dosages, and abrupt cessation and/or a reduction in dosage may precipitate withdrawal symptoms.  In patients who have developed tolerance, overdosage can still produce respiratory depression and death.  Therapy with anxiolytic, sedative, and hypnotic agents should be administered cautiously and for as brief a period as possible.  Addiction-prone individuals, such as those with a history of alcohol or substance abuse, should be under careful surveillance or medical supervision when treated with these agents.  In addition, it may be prudent to refrain from dispensing large quantities of medication to such patients.  After prolonged use or if dependency is suspected, withdrawal of medication should be undertaken gradually using a dosage-tapering schedule.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (18215, 23434, 'Pregabalin', 'Substance-Related Disorders', 'Anxiolytic, sedative, and hypnotic agents have the potential to cause dependence and abuse.  Tolerance as well as physical and psychological dependence can develop, particularly after prolonged use of excessive dosages, and abrupt cessation and/or a reduction in dosage may precipitate withdrawal symptoms.  In patients who have developed tolerance, overdosage can still produce respiratory depression and death.  Therapy with anxiolytic, sedative, and hypnotic agents should be administered cautiously and for as brief a period as possible.  Addiction-prone individuals, such as those with a history of alcohol or substance abuse, should be under careful surveillance or medical supervision when treated with these agents.  In addition, it may be prudent to refrain from dispensing large quantities of medication to such patients.  After prolonged use or if dependency is suspected, withdrawal of medication should be undertaken gradually using a dosage-tapering schedule.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (18216, 23446, 'Pregabalin', 'Substance-Related Disorders', 'Anxiolytic, sedative, and hypnotic agents have the potential to cause dependence and abuse.  Tolerance as well as physical and psychological dependence can develop, particularly after prolonged use of excessive dosages, and abrupt cessation and/or a reduction in dosage may precipitate withdrawal symptoms.  In patients who have developed tolerance, overdosage can still produce respiratory depression and death.  Therapy with anxiolytic, sedative, and hypnotic agents should be administered cautiously and for as brief a period as possible.  Addiction-prone individuals, such as those with a history of alcohol or substance abuse, should be under careful surveillance or medical supervision when treated with these agents.  In addition, it may be prudent to refrain from dispensing large quantities of medication to such patients.  After prolonged use or if dependency is suspected, withdrawal of medication should be undertaken gradually using a dosage-tapering schedule.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (18217, 23447, 'Pregabalin', 'Substance-Related Disorders', 'Anxiolytic, sedative, and hypnotic agents have the potential to cause dependence and abuse.  Tolerance as well as physical and psychological dependence can develop, particularly after prolonged use of excessive dosages, and abrupt cessation and/or a reduction in dosage may precipitate withdrawal symptoms.  In patients who have developed tolerance, overdosage can still produce respiratory depression and death.  Therapy with anxiolytic, sedative, and hypnotic agents should be administered cautiously and for as brief a period as possible.  Addiction-prone individuals, such as those with a history of alcohol or substance abuse, should be under careful surveillance or medical supervision when treated with these agents.  In addition, it may be prudent to refrain from dispensing large quantities of medication to such patients.  After prolonged use or if dependency is suspected, withdrawal of medication should be undertaken gradually using a dosage-tapering schedule.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (18218, 23448, 'Pregabalin', 'Substance-Related Disorders', 'Anxiolytic, sedative, and hypnotic agents have the potential to cause dependence and abuse.  Tolerance as well as physical and psychological dependence can develop, particularly after prolonged use of excessive dosages, and abrupt cessation and/or a reduction in dosage may precipitate withdrawal symptoms.  In patients who have developed tolerance, overdosage can still produce respiratory depression and death.  Therapy with anxiolytic, sedative, and hypnotic agents should be administered cautiously and for as brief a period as possible.  Addiction-prone individuals, such as those with a history of alcohol or substance abuse, should be under careful surveillance or medical supervision when treated with these agents.  In addition, it may be prudent to refrain from dispensing large quantities of medication to such patients.  After prolonged use or if dependency is suspected, withdrawal of medication should be undertaken gradually using a dosage-tapering schedule.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (18219, 23736, 'Pregabalin', 'Substance-Related Disorders', 'Anxiolytic, sedative, and hypnotic agents have the potential to cause dependence and abuse.  Tolerance as well as physical and psychological dependence can develop, particularly after prolonged use of excessive dosages, and abrupt cessation and/or a reduction in dosage may precipitate withdrawal symptoms.  In patients who have developed tolerance, overdosage can still produce respiratory depression and death.  Therapy with anxiolytic, sedative, and hypnotic agents should be administered cautiously and for as brief a period as possible.  Addiction-prone individuals, such as those with a history of alcohol or substance abuse, should be under careful surveillance or medical supervision when treated with these agents.  In addition, it may be prudent to refrain from dispensing large quantities of medication to such patients.  After prolonged use or if dependency is suspected, withdrawal of medication should be undertaken gradually using a dosage-tapering schedule.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (18220, 23737, 'Pregabalin', 'Substance-Related Disorders', 'Anxiolytic, sedative, and hypnotic agents have the potential to cause dependence and abuse.  Tolerance as well as physical and psychological dependence can develop, particularly after prolonged use of excessive dosages, and abrupt cessation and/or a reduction in dosage may precipitate withdrawal symptoms.  In patients who have developed tolerance, overdosage can still produce respiratory depression and death.  Therapy with anxiolytic, sedative, and hypnotic agents should be administered cautiously and for as brief a period as possible.  Addiction-prone individuals, such as those with a history of alcohol or substance abuse, should be under careful surveillance or medical supervision when treated with these agents.  In addition, it may be prudent to refrain from dispensing large quantities of medication to such patients.  After prolonged use or if dependency is suspected, withdrawal of medication should be undertaken gradually using a dosage-tapering schedule.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (18221, 24038, 'Pregabalin', 'Substance-Related Disorders', 'Anxiolytic, sedative, and hypnotic agents have the potential to cause dependence and abuse.  Tolerance as well as physical and psychological dependence can develop, particularly after prolonged use of excessive dosages, and abrupt cessation and/or a reduction in dosage may precipitate withdrawal symptoms.  In patients who have developed tolerance, overdosage can still produce respiratory depression and death.  Therapy with anxiolytic, sedative, and hypnotic agents should be administered cautiously and for as brief a period as possible.  Addiction-prone individuals, such as those with a history of alcohol or substance abuse, should be under careful surveillance or medical supervision when treated with these agents.  In addition, it may be prudent to refrain from dispensing large quantities of medication to such patients.  After prolonged use or if dependency is suspected, withdrawal of medication should be undertaken gradually using a dosage-tapering schedule.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (18222, 24455, 'Pregabalin', 'Substance-Related Disorders', 'Anxiolytic, sedative, and hypnotic agents have the potential to cause dependence and abuse.  Tolerance as well as physical and psychological dependence can develop, particularly after prolonged use of excessive dosages, and abrupt cessation and/or a reduction in dosage may precipitate withdrawal symptoms.  In patients who have developed tolerance, overdosage can still produce respiratory depression and death.  Therapy with anxiolytic, sedative, and hypnotic agents should be administered cautiously and for as brief a period as possible.  Addiction-prone individuals, such as those with a history of alcohol or substance abuse, should be under careful surveillance or medical supervision when treated with these agents.  In addition, it may be prudent to refrain from dispensing large quantities of medication to such patients.  After prolonged use or if dependency is suspected, withdrawal of medication should be undertaken gradually using a dosage-tapering schedule.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (18223, 24456, 'Pregabalin', 'Substance-Related Disorders', 'Anxiolytic, sedative, and hypnotic agents have the potential to cause dependence and abuse.  Tolerance as well as physical and psychological dependence can develop, particularly after prolonged use of excessive dosages, and abrupt cessation and/or a reduction in dosage may precipitate withdrawal symptoms.  In patients who have developed tolerance, overdosage can still produce respiratory depression and death.  Therapy with anxiolytic, sedative, and hypnotic agents should be administered cautiously and for as brief a period as possible.  Addiction-prone individuals, such as those with a history of alcohol or substance abuse, should be under careful surveillance or medical supervision when treated with these agents.  In addition, it may be prudent to refrain from dispensing large quantities of medication to such patients.  After prolonged use or if dependency is suspected, withdrawal of medication should be undertaken gradually using a dosage-tapering schedule.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (18224, 24457, 'Pregabalin', 'Substance-Related Disorders', 'Anxiolytic, sedative, and hypnotic agents have the potential to cause dependence and abuse.  Tolerance as well as physical and psychological dependence can develop, particularly after prolonged use of excessive dosages, and abrupt cessation and/or a reduction in dosage may precipitate withdrawal symptoms.  In patients who have developed tolerance, overdosage can still produce respiratory depression and death.  Therapy with anxiolytic, sedative, and hypnotic agents should be administered cautiously and for as brief a period as possible.  Addiction-prone individuals, such as those with a history of alcohol or substance abuse, should be under careful surveillance or medical supervision when treated with these agents.  In addition, it may be prudent to refrain from dispensing large quantities of medication to such patients.  After prolonged use or if dependency is suspected, withdrawal of medication should be undertaken gradually using a dosage-tapering schedule.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (18225, 24458, 'Pregabalin', 'Substance-Related Disorders', 'Anxiolytic, sedative, and hypnotic agents have the potential to cause dependence and abuse.  Tolerance as well as physical and psychological dependence can develop, particularly after prolonged use of excessive dosages, and abrupt cessation and/or a reduction in dosage may precipitate withdrawal symptoms.  In patients who have developed tolerance, overdosage can still produce respiratory depression and death.  Therapy with anxiolytic, sedative, and hypnotic agents should be administered cautiously and for as brief a period as possible.  Addiction-prone individuals, such as those with a history of alcohol or substance abuse, should be under careful surveillance or medical supervision when treated with these agents.  In addition, it may be prudent to refrain from dispensing large quantities of medication to such patients.  After prolonged use or if dependency is suspected, withdrawal of medication should be undertaken gradually using a dosage-tapering schedule.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (18226, 25156, 'Pregabalin', 'Substance-Related Disorders', 'Anxiolytic, sedative, and hypnotic agents have the potential to cause dependence and abuse.  Tolerance as well as physical and psychological dependence can develop, particularly after prolonged use of excessive dosages, and abrupt cessation and/or a reduction in dosage may precipitate withdrawal symptoms.  In patients who have developed tolerance, overdosage can still produce respiratory depression and death.  Therapy with anxiolytic, sedative, and hypnotic agents should be administered cautiously and for as brief a period as possible.  Addiction-prone individuals, such as those with a history of alcohol or substance abuse, should be under careful surveillance or medical supervision when treated with these agents.  In addition, it may be prudent to refrain from dispensing large quantities of medication to such patients.  After prolonged use or if dependency is suspected, withdrawal of medication should be undertaken gradually using a dosage-tapering schedule.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (18227, 25157, 'Pregabalin', 'Substance-Related Disorders', 'Anxiolytic, sedative, and hypnotic agents have the potential to cause dependence and abuse.  Tolerance as well as physical and psychological dependence can develop, particularly after prolonged use of excessive dosages, and abrupt cessation and/or a reduction in dosage may precipitate withdrawal symptoms.  In patients who have developed tolerance, overdosage can still produce respiratory depression and death.  Therapy with anxiolytic, sedative, and hypnotic agents should be administered cautiously and for as brief a period as possible.  Addiction-prone individuals, such as those with a history of alcohol or substance abuse, should be under careful surveillance or medical supervision when treated with these agents.  In addition, it may be prudent to refrain from dispensing large quantities of medication to such patients.  After prolonged use or if dependency is suspected, withdrawal of medication should be undertaken gradually using a dosage-tapering schedule.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (18228, 25158, 'Pregabalin', 'Substance-Related Disorders', 'Anxiolytic, sedative, and hypnotic agents have the potential to cause dependence and abuse.  Tolerance as well as physical and psychological dependence can develop, particularly after prolonged use of excessive dosages, and abrupt cessation and/or a reduction in dosage may precipitate withdrawal symptoms.  In patients who have developed tolerance, overdosage can still produce respiratory depression and death.  Therapy with anxiolytic, sedative, and hypnotic agents should be administered cautiously and for as brief a period as possible.  Addiction-prone individuals, such as those with a history of alcohol or substance abuse, should be under careful surveillance or medical supervision when treated with these agents.  In addition, it may be prudent to refrain from dispensing large quantities of medication to such patients.  After prolonged use or if dependency is suspected, withdrawal of medication should be undertaken gradually using a dosage-tapering schedule.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (18229, 25159, 'Pregabalin', 'Substance-Related Disorders', 'Anxiolytic, sedative, and hypnotic agents have the potential to cause dependence and abuse.  Tolerance as well as physical and psychological dependence can develop, particularly after prolonged use of excessive dosages, and abrupt cessation and/or a reduction in dosage may precipitate withdrawal symptoms.  In patients who have developed tolerance, overdosage can still produce respiratory depression and death.  Therapy with anxiolytic, sedative, and hypnotic agents should be administered cautiously and for as brief a period as possible.  Addiction-prone individuals, such as those with a history of alcohol or substance abuse, should be under careful surveillance or medical supervision when treated with these agents.  In addition, it may be prudent to refrain from dispensing large quantities of medication to such patients.  After prolonged use or if dependency is suspected, withdrawal of medication should be undertaken gradually using a dosage-tapering schedule.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (18230, 25160, 'Pregabalin', 'Substance-Related Disorders', 'Anxiolytic, sedative, and hypnotic agents have the potential to cause dependence and abuse.  Tolerance as well as physical and psychological dependence can develop, particularly after prolonged use of excessive dosages, and abrupt cessation and/or a reduction in dosage may precipitate withdrawal symptoms.  In patients who have developed tolerance, overdosage can still produce respiratory depression and death.  Therapy with anxiolytic, sedative, and hypnotic agents should be administered cautiously and for as brief a period as possible.  Addiction-prone individuals, such as those with a history of alcohol or substance abuse, should be under careful surveillance or medical supervision when treated with these agents.  In addition, it may be prudent to refrain from dispensing large quantities of medication to such patients.  After prolonged use or if dependency is suspected, withdrawal of medication should be undertaken gradually using a dosage-tapering schedule.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (18231, 25161, 'Pregabalin', 'Substance-Related Disorders', 'Anxiolytic, sedative, and hypnotic agents have the potential to cause dependence and abuse.  Tolerance as well as physical and psychological dependence can develop, particularly after prolonged use of excessive dosages, and abrupt cessation and/or a reduction in dosage may precipitate withdrawal symptoms.  In patients who have developed tolerance, overdosage can still produce respiratory depression and death.  Therapy with anxiolytic, sedative, and hypnotic agents should be administered cautiously and for as brief a period as possible.  Addiction-prone individuals, such as those with a history of alcohol or substance abuse, should be under careful surveillance or medical supervision when treated with these agents.  In addition, it may be prudent to refrain from dispensing large quantities of medication to such patients.  After prolonged use or if dependency is suspected, withdrawal of medication should be undertaken gradually using a dosage-tapering schedule.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (18232, 25162, 'Pregabalin', 'Substance-Related Disorders', 'Anxiolytic, sedative, and hypnotic agents have the potential to cause dependence and abuse.  Tolerance as well as physical and psychological dependence can develop, particularly after prolonged use of excessive dosages, and abrupt cessation and/or a reduction in dosage may precipitate withdrawal symptoms.  In patients who have developed tolerance, overdosage can still produce respiratory depression and death.  Therapy with anxiolytic, sedative, and hypnotic agents should be administered cautiously and for as brief a period as possible.  Addiction-prone individuals, such as those with a history of alcohol or substance abuse, should be under careful surveillance or medical supervision when treated with these agents.  In addition, it may be prudent to refrain from dispensing large quantities of medication to such patients.  After prolonged use or if dependency is suspected, withdrawal of medication should be undertaken gradually using a dosage-tapering schedule.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (18233, 25163, 'Pregabalin', 'Substance-Related Disorders', 'Anxiolytic, sedative, and hypnotic agents have the potential to cause dependence and abuse.  Tolerance as well as physical and psychological dependence can develop, particularly after prolonged use of excessive dosages, and abrupt cessation and/or a reduction in dosage may precipitate withdrawal symptoms.  In patients who have developed tolerance, overdosage can still produce respiratory depression and death.  Therapy with anxiolytic, sedative, and hypnotic agents should be administered cautiously and for as brief a period as possible.  Addiction-prone individuals, such as those with a history of alcohol or substance abuse, should be under careful surveillance or medical supervision when treated with these agents.  In addition, it may be prudent to refrain from dispensing large quantities of medication to such patients.  After prolonged use or if dependency is suspected, withdrawal of medication should be undertaken gradually using a dosage-tapering schedule.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (18234, 25164, 'Pregabalin', 'Substance-Related Disorders', 'Anxiolytic, sedative, and hypnotic agents have the potential to cause dependence and abuse.  Tolerance as well as physical and psychological dependence can develop, particularly after prolonged use of excessive dosages, and abrupt cessation and/or a reduction in dosage may precipitate withdrawal symptoms.  In patients who have developed tolerance, overdosage can still produce respiratory depression and death.  Therapy with anxiolytic, sedative, and hypnotic agents should be administered cautiously and for as brief a period as possible.  Addiction-prone individuals, such as those with a history of alcohol or substance abuse, should be under careful surveillance or medical supervision when treated with these agents.  In addition, it may be prudent to refrain from dispensing large quantities of medication to such patients.  After prolonged use or if dependency is suspected, withdrawal of medication should be undertaken gradually using a dosage-tapering schedule.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (18235, 25165, 'Pregabalin', 'Substance-Related Disorders', 'Anxiolytic, sedative, and hypnotic agents have the potential to cause dependence and abuse.  Tolerance as well as physical and psychological dependence can develop, particularly after prolonged use of excessive dosages, and abrupt cessation and/or a reduction in dosage may precipitate withdrawal symptoms.  In patients who have developed tolerance, overdosage can still produce respiratory depression and death.  Therapy with anxiolytic, sedative, and hypnotic agents should be administered cautiously and for as brief a period as possible.  Addiction-prone individuals, such as those with a history of alcohol or substance abuse, should be under careful surveillance or medical supervision when treated with these agents.  In addition, it may be prudent to refrain from dispensing large quantities of medication to such patients.  After prolonged use or if dependency is suspected, withdrawal of medication should be undertaken gradually using a dosage-tapering schedule.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (18236, 25166, 'Pregabalin', 'Substance-Related Disorders', 'Anxiolytic, sedative, and hypnotic agents have the potential to cause dependence and abuse.  Tolerance as well as physical and psychological dependence can develop, particularly after prolonged use of excessive dosages, and abrupt cessation and/or a reduction in dosage may precipitate withdrawal symptoms.  In patients who have developed tolerance, overdosage can still produce respiratory depression and death.  Therapy with anxiolytic, sedative, and hypnotic agents should be administered cautiously and for as brief a period as possible.  Addiction-prone individuals, such as those with a history of alcohol or substance abuse, should be under careful surveillance or medical supervision when treated with these agents.  In addition, it may be prudent to refrain from dispensing large quantities of medication to such patients.  After prolonged use or if dependency is suspected, withdrawal of medication should be undertaken gradually using a dosage-tapering schedule.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (18237, 25167, 'Pregabalin', 'Substance-Related Disorders', 'Anxiolytic, sedative, and hypnotic agents have the potential to cause dependence and abuse.  Tolerance as well as physical and psychological dependence can develop, particularly after prolonged use of excessive dosages, and abrupt cessation and/or a reduction in dosage may precipitate withdrawal symptoms.  In patients who have developed tolerance, overdosage can still produce respiratory depression and death.  Therapy with anxiolytic, sedative, and hypnotic agents should be administered cautiously and for as brief a period as possible.  Addiction-prone individuals, such as those with a history of alcohol or substance abuse, should be under careful surveillance or medical supervision when treated with these agents.  In addition, it may be prudent to refrain from dispensing large quantities of medication to such patients.  After prolonged use or if dependency is suspected, withdrawal of medication should be undertaken gradually using a dosage-tapering schedule.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (18238, 25168, 'Pregabalin', 'Substance-Related Disorders', 'Anxiolytic, sedative, and hypnotic agents have the potential to cause dependence and abuse.  Tolerance as well as physical and psychological dependence can develop, particularly after prolonged use of excessive dosages, and abrupt cessation and/or a reduction in dosage may precipitate withdrawal symptoms.  In patients who have developed tolerance, overdosage can still produce respiratory depression and death.  Therapy with anxiolytic, sedative, and hypnotic agents should be administered cautiously and for as brief a period as possible.  Addiction-prone individuals, such as those with a history of alcohol or substance abuse, should be under careful surveillance or medical supervision when treated with these agents.  In addition, it may be prudent to refrain from dispensing large quantities of medication to such patients.  After prolonged use or if dependency is suspected, withdrawal of medication should be undertaken gradually using a dosage-tapering schedule.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (18239, 25169, 'Pregabalin', 'Substance-Related Disorders', 'Anxiolytic, sedative, and hypnotic agents have the potential to cause dependence and abuse.  Tolerance as well as physical and psychological dependence can develop, particularly after prolonged use of excessive dosages, and abrupt cessation and/or a reduction in dosage may precipitate withdrawal symptoms.  In patients who have developed tolerance, overdosage can still produce respiratory depression and death.  Therapy with anxiolytic, sedative, and hypnotic agents should be administered cautiously and for as brief a period as possible.  Addiction-prone individuals, such as those with a history of alcohol or substance abuse, should be under careful surveillance or medical supervision when treated with these agents.  In addition, it may be prudent to refrain from dispensing large quantities of medication to such patients.  After prolonged use or if dependency is suspected, withdrawal of medication should be undertaken gradually using a dosage-tapering schedule.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (18240, 25170, 'Pregabalin', 'Substance-Related Disorders', 'Anxiolytic, sedative, and hypnotic agents have the potential to cause dependence and abuse.  Tolerance as well as physical and psychological dependence can develop, particularly after prolonged use of excessive dosages, and abrupt cessation and/or a reduction in dosage may precipitate withdrawal symptoms.  In patients who have developed tolerance, overdosage can still produce respiratory depression and death.  Therapy with anxiolytic, sedative, and hypnotic agents should be administered cautiously and for as brief a period as possible.  Addiction-prone individuals, such as those with a history of alcohol or substance abuse, should be under careful surveillance or medical supervision when treated with these agents.  In addition, it may be prudent to refrain from dispensing large quantities of medication to such patients.  After prolonged use or if dependency is suspected, withdrawal of medication should be undertaken gradually using a dosage-tapering schedule.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (18241, 25171, 'Pregabalin', 'Substance-Related Disorders', 'Anxiolytic, sedative, and hypnotic agents have the potential to cause dependence and abuse.  Tolerance as well as physical and psychological dependence can develop, particularly after prolonged use of excessive dosages, and abrupt cessation and/or a reduction in dosage may precipitate withdrawal symptoms.  In patients who have developed tolerance, overdosage can still produce respiratory depression and death.  Therapy with anxiolytic, sedative, and hypnotic agents should be administered cautiously and for as brief a period as possible.  Addiction-prone individuals, such as those with a history of alcohol or substance abuse, should be under careful surveillance or medical supervision when treated with these agents.  In addition, it may be prudent to refrain from dispensing large quantities of medication to such patients.  After prolonged use or if dependency is suspected, withdrawal of medication should be undertaken gradually using a dosage-tapering schedule.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (18242, 25172, 'Pregabalin', 'Substance-Related Disorders', 'Anxiolytic, sedative, and hypnotic agents have the potential to cause dependence and abuse.  Tolerance as well as physical and psychological dependence can develop, particularly after prolonged use of excessive dosages, and abrupt cessation and/or a reduction in dosage may precipitate withdrawal symptoms.  In patients who have developed tolerance, overdosage can still produce respiratory depression and death.  Therapy with anxiolytic, sedative, and hypnotic agents should be administered cautiously and for as brief a period as possible.  Addiction-prone individuals, such as those with a history of alcohol or substance abuse, should be under careful surveillance or medical supervision when treated with these agents.  In addition, it may be prudent to refrain from dispensing large quantities of medication to such patients.  After prolonged use or if dependency is suspected, withdrawal of medication should be undertaken gradually using a dosage-tapering schedule.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (18243, 25173, 'Pregabalin', 'Substance-Related Disorders', 'Anxiolytic, sedative, and hypnotic agents have the potential to cause dependence and abuse.  Tolerance as well as physical and psychological dependence can develop, particularly after prolonged use of excessive dosages, and abrupt cessation and/or a reduction in dosage may precipitate withdrawal symptoms.  In patients who have developed tolerance, overdosage can still produce respiratory depression and death.  Therapy with anxiolytic, sedative, and hypnotic agents should be administered cautiously and for as brief a period as possible.  Addiction-prone individuals, such as those with a history of alcohol or substance abuse, should be under careful surveillance or medical supervision when treated with these agents.  In addition, it may be prudent to refrain from dispensing large quantities of medication to such patients.  After prolonged use or if dependency is suspected, withdrawal of medication should be undertaken gradually using a dosage-tapering schedule.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (18244, 25184, 'Pregabalin', 'Substance-Related Disorders', 'Anxiolytic, sedative, and hypnotic agents have the potential to cause dependence and abuse.  Tolerance as well as physical and psychological dependence can develop, particularly after prolonged use of excessive dosages, and abrupt cessation and/or a reduction in dosage may precipitate withdrawal symptoms.  In patients who have developed tolerance, overdosage can still produce respiratory depression and death.  Therapy with anxiolytic, sedative, and hypnotic agents should be administered cautiously and for as brief a period as possible.  Addiction-prone individuals, such as those with a history of alcohol or substance abuse, should be under careful surveillance or medical supervision when treated with these agents.  In addition, it may be prudent to refrain from dispensing large quantities of medication to such patients.  After prolonged use or if dependency is suspected, withdrawal of medication should be undertaken gradually using a dosage-tapering schedule.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (18245, 25185, 'Pregabalin', 'Substance-Related Disorders', 'Anxiolytic, sedative, and hypnotic agents have the potential to cause dependence and abuse.  Tolerance as well as physical and psychological dependence can develop, particularly after prolonged use of excessive dosages, and abrupt cessation and/or a reduction in dosage may precipitate withdrawal symptoms.  In patients who have developed tolerance, overdosage can still produce respiratory depression and death.  Therapy with anxiolytic, sedative, and hypnotic agents should be administered cautiously and for as brief a period as possible.  Addiction-prone individuals, such as those with a history of alcohol or substance abuse, should be under careful surveillance or medical supervision when treated with these agents.  In addition, it may be prudent to refrain from dispensing large quantities of medication to such patients.  After prolonged use or if dependency is suspected, withdrawal of medication should be undertaken gradually using a dosage-tapering schedule.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (18246, 25531, 'Pregabalin', 'Substance-Related Disorders', 'Anxiolytic, sedative, and hypnotic agents have the potential to cause dependence and abuse.  Tolerance as well as physical and psychological dependence can develop, particularly after prolonged use of excessive dosages, and abrupt cessation and/or a reduction in dosage may precipitate withdrawal symptoms.  In patients who have developed tolerance, overdosage can still produce respiratory depression and death.  Therapy with anxiolytic, sedative, and hypnotic agents should be administered cautiously and for as brief a period as possible.  Addiction-prone individuals, such as those with a history of alcohol or substance abuse, should be under careful surveillance or medical supervision when treated with these agents.  In addition, it may be prudent to refrain from dispensing large quantities of medication to such patients.  After prolonged use or if dependency is suspected, withdrawal of medication should be undertaken gradually using a dosage-tapering schedule.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (18247, 25532, 'Pregabalin', 'Substance-Related Disorders', 'Anxiolytic, sedative, and hypnotic agents have the potential to cause dependence and abuse.  Tolerance as well as physical and psychological dependence can develop, particularly after prolonged use of excessive dosages, and abrupt cessation and/or a reduction in dosage may precipitate withdrawal symptoms.  In patients who have developed tolerance, overdosage can still produce respiratory depression and death.  Therapy with anxiolytic, sedative, and hypnotic agents should be administered cautiously and for as brief a period as possible.  Addiction-prone individuals, such as those with a history of alcohol or substance abuse, should be under careful surveillance or medical supervision when treated with these agents.  In addition, it may be prudent to refrain from dispensing large quantities of medication to such patients.  After prolonged use or if dependency is suspected, withdrawal of medication should be undertaken gradually using a dosage-tapering schedule.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (18248, 26350, 'Pregabalin', 'Substance-Related Disorders', 'Anxiolytic, sedative, and hypnotic agents have the potential to cause dependence and abuse.  Tolerance as well as physical and psychological dependence can develop, particularly after prolonged use of excessive dosages, and abrupt cessation and/or a reduction in dosage may precipitate withdrawal symptoms.  In patients who have developed tolerance, overdosage can still produce respiratory depression and death.  Therapy with anxiolytic, sedative, and hypnotic agents should be administered cautiously and for as brief a period as possible.  Addiction-prone individuals, such as those with a history of alcohol or substance abuse, should be under careful surveillance or medical supervision when treated with these agents.  In addition, it may be prudent to refrain from dispensing large quantities of medication to such patients.  After prolonged use or if dependency is suspected, withdrawal of medication should be undertaken gradually using a dosage-tapering schedule.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (18249, 26832, 'Pregabalin', 'Substance-Related Disorders', 'Anxiolytic, sedative, and hypnotic agents have the potential to cause dependence and abuse.  Tolerance as well as physical and psychological dependence can develop, particularly after prolonged use of excessive dosages, and abrupt cessation and/or a reduction in dosage may precipitate withdrawal symptoms.  In patients who have developed tolerance, overdosage can still produce respiratory depression and death.  Therapy with anxiolytic, sedative, and hypnotic agents should be administered cautiously and for as brief a period as possible.  Addiction-prone individuals, such as those with a history of alcohol or substance abuse, should be under careful surveillance or medical supervision when treated with these agents.  In addition, it may be prudent to refrain from dispensing large quantities of medication to such patients.  After prolonged use or if dependency is suspected, withdrawal of medication should be undertaken gradually using a dosage-tapering schedule.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (18250, 27113, 'Pregabalin', 'Substance-Related Disorders', 'Anxiolytic, sedative, and hypnotic agents have the potential to cause dependence and abuse.  Tolerance as well as physical and psychological dependence can develop, particularly after prolonged use of excessive dosages, and abrupt cessation and/or a reduction in dosage may precipitate withdrawal symptoms.  In patients who have developed tolerance, overdosage can still produce respiratory depression and death.  Therapy with anxiolytic, sedative, and hypnotic agents should be administered cautiously and for as brief a period as possible.  Addiction-prone individuals, such as those with a history of alcohol or substance abuse, should be under careful surveillance or medical supervision when treated with these agents.  In addition, it may be prudent to refrain from dispensing large quantities of medication to such patients.  After prolonged use or if dependency is suspected, withdrawal of medication should be undertaken gradually using a dosage-tapering schedule.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (18251, 27114, 'Pregabalin', 'Substance-Related Disorders', 'Anxiolytic, sedative, and hypnotic agents have the potential to cause dependence and abuse.  Tolerance as well as physical and psychological dependence can develop, particularly after prolonged use of excessive dosages, and abrupt cessation and/or a reduction in dosage may precipitate withdrawal symptoms.  In patients who have developed tolerance, overdosage can still produce respiratory depression and death.  Therapy with anxiolytic, sedative, and hypnotic agents should be administered cautiously and for as brief a period as possible.  Addiction-prone individuals, such as those with a history of alcohol or substance abuse, should be under careful surveillance or medical supervision when treated with these agents.  In addition, it may be prudent to refrain from dispensing large quantities of medication to such patients.  After prolonged use or if dependency is suspected, withdrawal of medication should be undertaken gradually using a dosage-tapering schedule.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (18252, 1160, 'Pregabalin', 'Depressive Disorder', 'Antiepileptic drugs (AEDs) have been associated with an increased risk of suicidal thoughts or behavior in patients taking these drugs for any indication.  Pooled analyses of 199 placebo-controlled clinical studies involving the use of 11 different AEDs showed that patients receiving AEDs had approximately twice the risk of suicidal thinking or behavior compared to patients receiving placebo.  AEDs should be administered cautiously in patients with depression or other psychiatric disorders.  The risk of suicidal thoughts and behavior should be carefully assessed against the risk of untreated illness, bearing in mind that epilepsy and many other conditions for which AEDs are prescribed are themselves associated with morbidity and mortality and an increased risk of suicidal thoughts and behavior.  Patients, caregivers, and families should be alert to the emergence or worsening of signs and symptoms of depression, any unusual changes in mood or behavior, or the emergence of suicidal thoughts or behavior.  If patients have symptoms of suicidal ideation or behavior, a dosage reduction or treatment discontinuation should be considered.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (18253, 1161, 'Pregabalin', 'Depressive Disorder', 'Antiepileptic drugs (AEDs) have been associated with an increased risk of suicidal thoughts or behavior in patients taking these drugs for any indication.  Pooled analyses of 199 placebo-controlled clinical studies involving the use of 11 different AEDs showed that patients receiving AEDs had approximately twice the risk of suicidal thinking or behavior compared to patients receiving placebo.  AEDs should be administered cautiously in patients with depression or other psychiatric disorders.  The risk of suicidal thoughts and behavior should be carefully assessed against the risk of untreated illness, bearing in mind that epilepsy and many other conditions for which AEDs are prescribed are themselves associated with morbidity and mortality and an increased risk of suicidal thoughts and behavior.  Patients, caregivers, and families should be alert to the emergence or worsening of signs and symptoms of depression, any unusual changes in mood or behavior, or the emergence of suicidal thoughts or behavior.  If patients have symptoms of suicidal ideation or behavior, a dosage reduction or treatment discontinuation should be considered.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (18254, 3180, 'Pregabalin', 'Depressive Disorder', 'Antiepileptic drugs (AEDs) have been associated with an increased risk of suicidal thoughts or behavior in patients taking these drugs for any indication.  Pooled analyses of 199 placebo-controlled clinical studies involving the use of 11 different AEDs showed that patients receiving AEDs had approximately twice the risk of suicidal thinking or behavior compared to patients receiving placebo.  AEDs should be administered cautiously in patients with depression or other psychiatric disorders.  The risk of suicidal thoughts and behavior should be carefully assessed against the risk of untreated illness, bearing in mind that epilepsy and many other conditions for which AEDs are prescribed are themselves associated with morbidity and mortality and an increased risk of suicidal thoughts and behavior.  Patients, caregivers, and families should be alert to the emergence or worsening of signs and symptoms of depression, any unusual changes in mood or behavior, or the emergence of suicidal thoughts or behavior.  If patients have symptoms of suicidal ideation or behavior, a dosage reduction or treatment discontinuation should be considered.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (18255, 5282, 'Pregabalin', 'Depressive Disorder', 'Antiepileptic drugs (AEDs) have been associated with an increased risk of suicidal thoughts or behavior in patients taking these drugs for any indication.  Pooled analyses of 199 placebo-controlled clinical studies involving the use of 11 different AEDs showed that patients receiving AEDs had approximately twice the risk of suicidal thinking or behavior compared to patients receiving placebo.  AEDs should be administered cautiously in patients with depression or other psychiatric disorders.  The risk of suicidal thoughts and behavior should be carefully assessed against the risk of untreated illness, bearing in mind that epilepsy and many other conditions for which AEDs are prescribed are themselves associated with morbidity and mortality and an increased risk of suicidal thoughts and behavior.  Patients, caregivers, and families should be alert to the emergence or worsening of signs and symptoms of depression, any unusual changes in mood or behavior, or the emergence of suicidal thoughts or behavior.  If patients have symptoms of suicidal ideation or behavior, a dosage reduction or treatment discontinuation should be considered.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (18256, 5586, 'Pregabalin', 'Depressive Disorder', 'Antiepileptic drugs (AEDs) have been associated with an increased risk of suicidal thoughts or behavior in patients taking these drugs for any indication.  Pooled analyses of 199 placebo-controlled clinical studies involving the use of 11 different AEDs showed that patients receiving AEDs had approximately twice the risk of suicidal thinking or behavior compared to patients receiving placebo.  AEDs should be administered cautiously in patients with depression or other psychiatric disorders.  The risk of suicidal thoughts and behavior should be carefully assessed against the risk of untreated illness, bearing in mind that epilepsy and many other conditions for which AEDs are prescribed are themselves associated with morbidity and mortality and an increased risk of suicidal thoughts and behavior.  Patients, caregivers, and families should be alert to the emergence or worsening of signs and symptoms of depression, any unusual changes in mood or behavior, or the emergence of suicidal thoughts or behavior.  If patients have symptoms of suicidal ideation or behavior, a dosage reduction or treatment discontinuation should be considered.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (18257, 6080, 'Pregabalin', 'Depressive Disorder', 'Antiepileptic drugs (AEDs) have been associated with an increased risk of suicidal thoughts or behavior in patients taking these drugs for any indication.  Pooled analyses of 199 placebo-controlled clinical studies involving the use of 11 different AEDs showed that patients receiving AEDs had approximately twice the risk of suicidal thinking or behavior compared to patients receiving placebo.  AEDs should be administered cautiously in patients with depression or other psychiatric disorders.  The risk of suicidal thoughts and behavior should be carefully assessed against the risk of untreated illness, bearing in mind that epilepsy and many other conditions for which AEDs are prescribed are themselves associated with morbidity and mortality and an increased risk of suicidal thoughts and behavior.  Patients, caregivers, and families should be alert to the emergence or worsening of signs and symptoms of depression, any unusual changes in mood or behavior, or the emergence of suicidal thoughts or behavior.  If patients have symptoms of suicidal ideation or behavior, a dosage reduction or treatment discontinuation should be considered.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (18258, 6575, 'Pregabalin', 'Depressive Disorder', 'Antiepileptic drugs (AEDs) have been associated with an increased risk of suicidal thoughts or behavior in patients taking these drugs for any indication.  Pooled analyses of 199 placebo-controlled clinical studies involving the use of 11 different AEDs showed that patients receiving AEDs had approximately twice the risk of suicidal thinking or behavior compared to patients receiving placebo.  AEDs should be administered cautiously in patients with depression or other psychiatric disorders.  The risk of suicidal thoughts and behavior should be carefully assessed against the risk of untreated illness, bearing in mind that epilepsy and many other conditions for which AEDs are prescribed are themselves associated with morbidity and mortality and an increased risk of suicidal thoughts and behavior.  Patients, caregivers, and families should be alert to the emergence or worsening of signs and symptoms of depression, any unusual changes in mood or behavior, or the emergence of suicidal thoughts or behavior.  If patients have symptoms of suicidal ideation or behavior, a dosage reduction or treatment discontinuation should be considered.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (18259, 6577, 'Pregabalin', 'Depressive Disorder', 'Antiepileptic drugs (AEDs) have been associated with an increased risk of suicidal thoughts or behavior in patients taking these drugs for any indication.  Pooled analyses of 199 placebo-controlled clinical studies involving the use of 11 different AEDs showed that patients receiving AEDs had approximately twice the risk of suicidal thinking or behavior compared to patients receiving placebo.  AEDs should be administered cautiously in patients with depression or other psychiatric disorders.  The risk of suicidal thoughts and behavior should be carefully assessed against the risk of untreated illness, bearing in mind that epilepsy and many other conditions for which AEDs are prescribed are themselves associated with morbidity and mortality and an increased risk of suicidal thoughts and behavior.  Patients, caregivers, and families should be alert to the emergence or worsening of signs and symptoms of depression, any unusual changes in mood or behavior, or the emergence of suicidal thoughts or behavior.  If patients have symptoms of suicidal ideation or behavior, a dosage reduction or treatment discontinuation should be considered.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (18260, 6819, 'Pregabalin', 'Depressive Disorder', 'Antiepileptic drugs (AEDs) have been associated with an increased risk of suicidal thoughts or behavior in patients taking these drugs for any indication.  Pooled analyses of 199 placebo-controlled clinical studies involving the use of 11 different AEDs showed that patients receiving AEDs had approximately twice the risk of suicidal thinking or behavior compared to patients receiving placebo.  AEDs should be administered cautiously in patients with depression or other psychiatric disorders.  The risk of suicidal thoughts and behavior should be carefully assessed against the risk of untreated illness, bearing in mind that epilepsy and many other conditions for which AEDs are prescribed are themselves associated with morbidity and mortality and an increased risk of suicidal thoughts and behavior.  Patients, caregivers, and families should be alert to the emergence or worsening of signs and symptoms of depression, any unusual changes in mood or behavior, or the emergence of suicidal thoughts or behavior.  If patients have symptoms of suicidal ideation or behavior, a dosage reduction or treatment discontinuation should be considered.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (18261, 6821, 'Pregabalin', 'Depressive Disorder', 'Antiepileptic drugs (AEDs) have been associated with an increased risk of suicidal thoughts or behavior in patients taking these drugs for any indication.  Pooled analyses of 199 placebo-controlled clinical studies involving the use of 11 different AEDs showed that patients receiving AEDs had approximately twice the risk of suicidal thinking or behavior compared to patients receiving placebo.  AEDs should be administered cautiously in patients with depression or other psychiatric disorders.  The risk of suicidal thoughts and behavior should be carefully assessed against the risk of untreated illness, bearing in mind that epilepsy and many other conditions for which AEDs are prescribed are themselves associated with morbidity and mortality and an increased risk of suicidal thoughts and behavior.  Patients, caregivers, and families should be alert to the emergence or worsening of signs and symptoms of depression, any unusual changes in mood or behavior, or the emergence of suicidal thoughts or behavior.  If patients have symptoms of suicidal ideation or behavior, a dosage reduction or treatment discontinuation should be considered.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (18262, 6824, 'Pregabalin', 'Depressive Disorder', 'Antiepileptic drugs (AEDs) have been associated with an increased risk of suicidal thoughts or behavior in patients taking these drugs for any indication.  Pooled analyses of 199 placebo-controlled clinical studies involving the use of 11 different AEDs showed that patients receiving AEDs had approximately twice the risk of suicidal thinking or behavior compared to patients receiving placebo.  AEDs should be administered cautiously in patients with depression or other psychiatric disorders.  The risk of suicidal thoughts and behavior should be carefully assessed against the risk of untreated illness, bearing in mind that epilepsy and many other conditions for which AEDs are prescribed are themselves associated with morbidity and mortality and an increased risk of suicidal thoughts and behavior.  Patients, caregivers, and families should be alert to the emergence or worsening of signs and symptoms of depression, any unusual changes in mood or behavior, or the emergence of suicidal thoughts or behavior.  If patients have symptoms of suicidal ideation or behavior, a dosage reduction or treatment discontinuation should be considered.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (18263, 7625, 'Pregabalin', 'Depressive Disorder', 'Antiepileptic drugs (AEDs) have been associated with an increased risk of suicidal thoughts or behavior in patients taking these drugs for any indication.  Pooled analyses of 199 placebo-controlled clinical studies involving the use of 11 different AEDs showed that patients receiving AEDs had approximately twice the risk of suicidal thinking or behavior compared to patients receiving placebo.  AEDs should be administered cautiously in patients with depression or other psychiatric disorders.  The risk of suicidal thoughts and behavior should be carefully assessed against the risk of untreated illness, bearing in mind that epilepsy and many other conditions for which AEDs are prescribed are themselves associated with morbidity and mortality and an increased risk of suicidal thoughts and behavior.  Patients, caregivers, and families should be alert to the emergence or worsening of signs and symptoms of depression, any unusual changes in mood or behavior, or the emergence of suicidal thoughts or behavior.  If patients have symptoms of suicidal ideation or behavior, a dosage reduction or treatment discontinuation should be considered.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (18264, 7628, 'Pregabalin', 'Depressive Disorder', 'Antiepileptic drugs (AEDs) have been associated with an increased risk of suicidal thoughts or behavior in patients taking these drugs for any indication.  Pooled analyses of 199 placebo-controlled clinical studies involving the use of 11 different AEDs showed that patients receiving AEDs had approximately twice the risk of suicidal thinking or behavior compared to patients receiving placebo.  AEDs should be administered cautiously in patients with depression or other psychiatric disorders.  The risk of suicidal thoughts and behavior should be carefully assessed against the risk of untreated illness, bearing in mind that epilepsy and many other conditions for which AEDs are prescribed are themselves associated with morbidity and mortality and an increased risk of suicidal thoughts and behavior.  Patients, caregivers, and families should be alert to the emergence or worsening of signs and symptoms of depression, any unusual changes in mood or behavior, or the emergence of suicidal thoughts or behavior.  If patients have symptoms of suicidal ideation or behavior, a dosage reduction or treatment discontinuation should be considered.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (18265, 7633, 'Pregabalin', 'Depressive Disorder', 'Antiepileptic drugs (AEDs) have been associated with an increased risk of suicidal thoughts or behavior in patients taking these drugs for any indication.  Pooled analyses of 199 placebo-controlled clinical studies involving the use of 11 different AEDs showed that patients receiving AEDs had approximately twice the risk of suicidal thinking or behavior compared to patients receiving placebo.  AEDs should be administered cautiously in patients with depression or other psychiatric disorders.  The risk of suicidal thoughts and behavior should be carefully assessed against the risk of untreated illness, bearing in mind that epilepsy and many other conditions for which AEDs are prescribed are themselves associated with morbidity and mortality and an increased risk of suicidal thoughts and behavior.  Patients, caregivers, and families should be alert to the emergence or worsening of signs and symptoms of depression, any unusual changes in mood or behavior, or the emergence of suicidal thoughts or behavior.  If patients have symptoms of suicidal ideation or behavior, a dosage reduction or treatment discontinuation should be considered.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (18266, 10352, 'Pregabalin', 'Depressive Disorder', 'Antiepileptic drugs (AEDs) have been associated with an increased risk of suicidal thoughts or behavior in patients taking these drugs for any indication.  Pooled analyses of 199 placebo-controlled clinical studies involving the use of 11 different AEDs showed that patients receiving AEDs had approximately twice the risk of suicidal thinking or behavior compared to patients receiving placebo.  AEDs should be administered cautiously in patients with depression or other psychiatric disorders.  The risk of suicidal thoughts and behavior should be carefully assessed against the risk of untreated illness, bearing in mind that epilepsy and many other conditions for which AEDs are prescribed are themselves associated with morbidity and mortality and an increased risk of suicidal thoughts and behavior.  Patients, caregivers, and families should be alert to the emergence or worsening of signs and symptoms of depression, any unusual changes in mood or behavior, or the emergence of suicidal thoughts or behavior.  If patients have symptoms of suicidal ideation or behavior, a dosage reduction or treatment discontinuation should be considered.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (18267, 13189, 'Pregabalin', 'Depressive Disorder', 'Antiepileptic drugs (AEDs) have been associated with an increased risk of suicidal thoughts or behavior in patients taking these drugs for any indication.  Pooled analyses of 199 placebo-controlled clinical studies involving the use of 11 different AEDs showed that patients receiving AEDs had approximately twice the risk of suicidal thinking or behavior compared to patients receiving placebo.  AEDs should be administered cautiously in patients with depression or other psychiatric disorders.  The risk of suicidal thoughts and behavior should be carefully assessed against the risk of untreated illness, bearing in mind that epilepsy and many other conditions for which AEDs are prescribed are themselves associated with morbidity and mortality and an increased risk of suicidal thoughts and behavior.  Patients, caregivers, and families should be alert to the emergence or worsening of signs and symptoms of depression, any unusual changes in mood or behavior, or the emergence of suicidal thoughts or behavior.  If patients have symptoms of suicidal ideation or behavior, a dosage reduction or treatment discontinuation should be considered.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (18268, 14739, 'Pregabalin', 'Depressive Disorder', 'Antiepileptic drugs (AEDs) have been associated with an increased risk of suicidal thoughts or behavior in patients taking these drugs for any indication.  Pooled analyses of 199 placebo-controlled clinical studies involving the use of 11 different AEDs showed that patients receiving AEDs had approximately twice the risk of suicidal thinking or behavior compared to patients receiving placebo.  AEDs should be administered cautiously in patients with depression or other psychiatric disorders.  The risk of suicidal thoughts and behavior should be carefully assessed against the risk of untreated illness, bearing in mind that epilepsy and many other conditions for which AEDs are prescribed are themselves associated with morbidity and mortality and an increased risk of suicidal thoughts and behavior.  Patients, caregivers, and families should be alert to the emergence or worsening of signs and symptoms of depression, any unusual changes in mood or behavior, or the emergence of suicidal thoughts or behavior.  If patients have symptoms of suicidal ideation or behavior, a dosage reduction or treatment discontinuation should be considered.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (18269, 14888, 'Pregabalin', 'Depressive Disorder', 'Antiepileptic drugs (AEDs) have been associated with an increased risk of suicidal thoughts or behavior in patients taking these drugs for any indication.  Pooled analyses of 199 placebo-controlled clinical studies involving the use of 11 different AEDs showed that patients receiving AEDs had approximately twice the risk of suicidal thinking or behavior compared to patients receiving placebo.  AEDs should be administered cautiously in patients with depression or other psychiatric disorders.  The risk of suicidal thoughts and behavior should be carefully assessed against the risk of untreated illness, bearing in mind that epilepsy and many other conditions for which AEDs are prescribed are themselves associated with morbidity and mortality and an increased risk of suicidal thoughts and behavior.  Patients, caregivers, and families should be alert to the emergence or worsening of signs and symptoms of depression, any unusual changes in mood or behavior, or the emergence of suicidal thoughts or behavior.  If patients have symptoms of suicidal ideation or behavior, a dosage reduction or treatment discontinuation should be considered.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (18270, 16781, 'Pregabalin', 'Depressive Disorder', 'Antiepileptic drugs (AEDs) have been associated with an increased risk of suicidal thoughts or behavior in patients taking these drugs for any indication.  Pooled analyses of 199 placebo-controlled clinical studies involving the use of 11 different AEDs showed that patients receiving AEDs had approximately twice the risk of suicidal thinking or behavior compared to patients receiving placebo.  AEDs should be administered cautiously in patients with depression or other psychiatric disorders.  The risk of suicidal thoughts and behavior should be carefully assessed against the risk of untreated illness, bearing in mind that epilepsy and many other conditions for which AEDs are prescribed are themselves associated with morbidity and mortality and an increased risk of suicidal thoughts and behavior.  Patients, caregivers, and families should be alert to the emergence or worsening of signs and symptoms of depression, any unusual changes in mood or behavior, or the emergence of suicidal thoughts or behavior.  If patients have symptoms of suicidal ideation or behavior, a dosage reduction or treatment discontinuation should be considered.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (18271, 17266, 'Pregabalin', 'Depressive Disorder', 'Antiepileptic drugs (AEDs) have been associated with an increased risk of suicidal thoughts or behavior in patients taking these drugs for any indication.  Pooled analyses of 199 placebo-controlled clinical studies involving the use of 11 different AEDs showed that patients receiving AEDs had approximately twice the risk of suicidal thinking or behavior compared to patients receiving placebo.  AEDs should be administered cautiously in patients with depression or other psychiatric disorders.  The risk of suicidal thoughts and behavior should be carefully assessed against the risk of untreated illness, bearing in mind that epilepsy and many other conditions for which AEDs are prescribed are themselves associated with morbidity and mortality and an increased risk of suicidal thoughts and behavior.  Patients, caregivers, and families should be alert to the emergence or worsening of signs and symptoms of depression, any unusual changes in mood or behavior, or the emergence of suicidal thoughts or behavior.  If patients have symptoms of suicidal ideation or behavior, a dosage reduction or treatment discontinuation should be considered.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (18272, 17267, 'Pregabalin', 'Depressive Disorder', 'Antiepileptic drugs (AEDs) have been associated with an increased risk of suicidal thoughts or behavior in patients taking these drugs for any indication.  Pooled analyses of 199 placebo-controlled clinical studies involving the use of 11 different AEDs showed that patients receiving AEDs had approximately twice the risk of suicidal thinking or behavior compared to patients receiving placebo.  AEDs should be administered cautiously in patients with depression or other psychiatric disorders.  The risk of suicidal thoughts and behavior should be carefully assessed against the risk of untreated illness, bearing in mind that epilepsy and many other conditions for which AEDs are prescribed are themselves associated with morbidity and mortality and an increased risk of suicidal thoughts and behavior.  Patients, caregivers, and families should be alert to the emergence or worsening of signs and symptoms of depression, any unusual changes in mood or behavior, or the emergence of suicidal thoughts or behavior.  If patients have symptoms of suicidal ideation or behavior, a dosage reduction or treatment discontinuation should be considered.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (18273, 17268, 'Pregabalin', 'Depressive Disorder', 'Antiepileptic drugs (AEDs) have been associated with an increased risk of suicidal thoughts or behavior in patients taking these drugs for any indication.  Pooled analyses of 199 placebo-controlled clinical studies involving the use of 11 different AEDs showed that patients receiving AEDs had approximately twice the risk of suicidal thinking or behavior compared to patients receiving placebo.  AEDs should be administered cautiously in patients with depression or other psychiatric disorders.  The risk of suicidal thoughts and behavior should be carefully assessed against the risk of untreated illness, bearing in mind that epilepsy and many other conditions for which AEDs are prescribed are themselves associated with morbidity and mortality and an increased risk of suicidal thoughts and behavior.  Patients, caregivers, and families should be alert to the emergence or worsening of signs and symptoms of depression, any unusual changes in mood or behavior, or the emergence of suicidal thoughts or behavior.  If patients have symptoms of suicidal ideation or behavior, a dosage reduction or treatment discontinuation should be considered.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (18274, 17269, 'Pregabalin', 'Depressive Disorder', 'Antiepileptic drugs (AEDs) have been associated with an increased risk of suicidal thoughts or behavior in patients taking these drugs for any indication.  Pooled analyses of 199 placebo-controlled clinical studies involving the use of 11 different AEDs showed that patients receiving AEDs had approximately twice the risk of suicidal thinking or behavior compared to patients receiving placebo.  AEDs should be administered cautiously in patients with depression or other psychiatric disorders.  The risk of suicidal thoughts and behavior should be carefully assessed against the risk of untreated illness, bearing in mind that epilepsy and many other conditions for which AEDs are prescribed are themselves associated with morbidity and mortality and an increased risk of suicidal thoughts and behavior.  Patients, caregivers, and families should be alert to the emergence or worsening of signs and symptoms of depression, any unusual changes in mood or behavior, or the emergence of suicidal thoughts or behavior.  If patients have symptoms of suicidal ideation or behavior, a dosage reduction or treatment discontinuation should be considered.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (18275, 17270, 'Pregabalin', 'Depressive Disorder', 'Antiepileptic drugs (AEDs) have been associated with an increased risk of suicidal thoughts or behavior in patients taking these drugs for any indication.  Pooled analyses of 199 placebo-controlled clinical studies involving the use of 11 different AEDs showed that patients receiving AEDs had approximately twice the risk of suicidal thinking or behavior compared to patients receiving placebo.  AEDs should be administered cautiously in patients with depression or other psychiatric disorders.  The risk of suicidal thoughts and behavior should be carefully assessed against the risk of untreated illness, bearing in mind that epilepsy and many other conditions for which AEDs are prescribed are themselves associated with morbidity and mortality and an increased risk of suicidal thoughts and behavior.  Patients, caregivers, and families should be alert to the emergence or worsening of signs and symptoms of depression, any unusual changes in mood or behavior, or the emergence of suicidal thoughts or behavior.  If patients have symptoms of suicidal ideation or behavior, a dosage reduction or treatment discontinuation should be considered.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (18276, 19333, 'Pregabalin', 'Depressive Disorder', 'Antiepileptic drugs (AEDs) have been associated with an increased risk of suicidal thoughts or behavior in patients taking these drugs for any indication.  Pooled analyses of 199 placebo-controlled clinical studies involving the use of 11 different AEDs showed that patients receiving AEDs had approximately twice the risk of suicidal thinking or behavior compared to patients receiving placebo.  AEDs should be administered cautiously in patients with depression or other psychiatric disorders.  The risk of suicidal thoughts and behavior should be carefully assessed against the risk of untreated illness, bearing in mind that epilepsy and many other conditions for which AEDs are prescribed are themselves associated with morbidity and mortality and an increased risk of suicidal thoughts and behavior.  Patients, caregivers, and families should be alert to the emergence or worsening of signs and symptoms of depression, any unusual changes in mood or behavior, or the emergence of suicidal thoughts or behavior.  If patients have symptoms of suicidal ideation or behavior, a dosage reduction or treatment discontinuation should be considered.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (18277, 19539, 'Pregabalin', 'Depressive Disorder', 'Antiepileptic drugs (AEDs) have been associated with an increased risk of suicidal thoughts or behavior in patients taking these drugs for any indication.  Pooled analyses of 199 placebo-controlled clinical studies involving the use of 11 different AEDs showed that patients receiving AEDs had approximately twice the risk of suicidal thinking or behavior compared to patients receiving placebo.  AEDs should be administered cautiously in patients with depression or other psychiatric disorders.  The risk of suicidal thoughts and behavior should be carefully assessed against the risk of untreated illness, bearing in mind that epilepsy and many other conditions for which AEDs are prescribed are themselves associated with morbidity and mortality and an increased risk of suicidal thoughts and behavior.  Patients, caregivers, and families should be alert to the emergence or worsening of signs and symptoms of depression, any unusual changes in mood or behavior, or the emergence of suicidal thoughts or behavior.  If patients have symptoms of suicidal ideation or behavior, a dosage reduction or treatment discontinuation should be considered.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (18278, 19556, 'Pregabalin', 'Depressive Disorder', 'Antiepileptic drugs (AEDs) have been associated with an increased risk of suicidal thoughts or behavior in patients taking these drugs for any indication.  Pooled analyses of 199 placebo-controlled clinical studies involving the use of 11 different AEDs showed that patients receiving AEDs had approximately twice the risk of suicidal thinking or behavior compared to patients receiving placebo.  AEDs should be administered cautiously in patients with depression or other psychiatric disorders.  The risk of suicidal thoughts and behavior should be carefully assessed against the risk of untreated illness, bearing in mind that epilepsy and many other conditions for which AEDs are prescribed are themselves associated with morbidity and mortality and an increased risk of suicidal thoughts and behavior.  Patients, caregivers, and families should be alert to the emergence or worsening of signs and symptoms of depression, any unusual changes in mood or behavior, or the emergence of suicidal thoughts or behavior.  If patients have symptoms of suicidal ideation or behavior, a dosage reduction or treatment discontinuation should be considered.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (18279, 19871, 'Pregabalin', 'Depressive Disorder', 'Antiepileptic drugs (AEDs) have been associated with an increased risk of suicidal thoughts or behavior in patients taking these drugs for any indication.  Pooled analyses of 199 placebo-controlled clinical studies involving the use of 11 different AEDs showed that patients receiving AEDs had approximately twice the risk of suicidal thinking or behavior compared to patients receiving placebo.  AEDs should be administered cautiously in patients with depression or other psychiatric disorders.  The risk of suicidal thoughts and behavior should be carefully assessed against the risk of untreated illness, bearing in mind that epilepsy and many other conditions for which AEDs are prescribed are themselves associated with morbidity and mortality and an increased risk of suicidal thoughts and behavior.  Patients, caregivers, and families should be alert to the emergence or worsening of signs and symptoms of depression, any unusual changes in mood or behavior, or the emergence of suicidal thoughts or behavior.  If patients have symptoms of suicidal ideation or behavior, a dosage reduction or treatment discontinuation should be considered.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (18280, 19872, 'Pregabalin', 'Depressive Disorder', 'Antiepileptic drugs (AEDs) have been associated with an increased risk of suicidal thoughts or behavior in patients taking these drugs for any indication.  Pooled analyses of 199 placebo-controlled clinical studies involving the use of 11 different AEDs showed that patients receiving AEDs had approximately twice the risk of suicidal thinking or behavior compared to patients receiving placebo.  AEDs should be administered cautiously in patients with depression or other psychiatric disorders.  The risk of suicidal thoughts and behavior should be carefully assessed against the risk of untreated illness, bearing in mind that epilepsy and many other conditions for which AEDs are prescribed are themselves associated with morbidity and mortality and an increased risk of suicidal thoughts and behavior.  Patients, caregivers, and families should be alert to the emergence or worsening of signs and symptoms of depression, any unusual changes in mood or behavior, or the emergence of suicidal thoughts or behavior.  If patients have symptoms of suicidal ideation or behavior, a dosage reduction or treatment discontinuation should be considered.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (18281, 20442, 'Pregabalin', 'Depressive Disorder', 'Antiepileptic drugs (AEDs) have been associated with an increased risk of suicidal thoughts or behavior in patients taking these drugs for any indication.  Pooled analyses of 199 placebo-controlled clinical studies involving the use of 11 different AEDs showed that patients receiving AEDs had approximately twice the risk of suicidal thinking or behavior compared to patients receiving placebo.  AEDs should be administered cautiously in patients with depression or other psychiatric disorders.  The risk of suicidal thoughts and behavior should be carefully assessed against the risk of untreated illness, bearing in mind that epilepsy and many other conditions for which AEDs are prescribed are themselves associated with morbidity and mortality and an increased risk of suicidal thoughts and behavior.  Patients, caregivers, and families should be alert to the emergence or worsening of signs and symptoms of depression, any unusual changes in mood or behavior, or the emergence of suicidal thoughts or behavior.  If patients have symptoms of suicidal ideation or behavior, a dosage reduction or treatment discontinuation should be considered.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (18282, 21299, 'Pregabalin', 'Depressive Disorder', 'Antiepileptic drugs (AEDs) have been associated with an increased risk of suicidal thoughts or behavior in patients taking these drugs for any indication.  Pooled analyses of 199 placebo-controlled clinical studies involving the use of 11 different AEDs showed that patients receiving AEDs had approximately twice the risk of suicidal thinking or behavior compared to patients receiving placebo.  AEDs should be administered cautiously in patients with depression or other psychiatric disorders.  The risk of suicidal thoughts and behavior should be carefully assessed against the risk of untreated illness, bearing in mind that epilepsy and many other conditions for which AEDs are prescribed are themselves associated with morbidity and mortality and an increased risk of suicidal thoughts and behavior.  Patients, caregivers, and families should be alert to the emergence or worsening of signs and symptoms of depression, any unusual changes in mood or behavior, or the emergence of suicidal thoughts or behavior.  If patients have symptoms of suicidal ideation or behavior, a dosage reduction or treatment discontinuation should be considered.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (18283, 21301, 'Pregabalin', 'Depressive Disorder', 'Antiepileptic drugs (AEDs) have been associated with an increased risk of suicidal thoughts or behavior in patients taking these drugs for any indication.  Pooled analyses of 199 placebo-controlled clinical studies involving the use of 11 different AEDs showed that patients receiving AEDs had approximately twice the risk of suicidal thinking or behavior compared to patients receiving placebo.  AEDs should be administered cautiously in patients with depression or other psychiatric disorders.  The risk of suicidal thoughts and behavior should be carefully assessed against the risk of untreated illness, bearing in mind that epilepsy and many other conditions for which AEDs are prescribed are themselves associated with morbidity and mortality and an increased risk of suicidal thoughts and behavior.  Patients, caregivers, and families should be alert to the emergence or worsening of signs and symptoms of depression, any unusual changes in mood or behavior, or the emergence of suicidal thoughts or behavior.  If patients have symptoms of suicidal ideation or behavior, a dosage reduction or treatment discontinuation should be considered.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (18284, 21303, 'Pregabalin', 'Depressive Disorder', 'Antiepileptic drugs (AEDs) have been associated with an increased risk of suicidal thoughts or behavior in patients taking these drugs for any indication.  Pooled analyses of 199 placebo-controlled clinical studies involving the use of 11 different AEDs showed that patients receiving AEDs had approximately twice the risk of suicidal thinking or behavior compared to patients receiving placebo.  AEDs should be administered cautiously in patients with depression or other psychiatric disorders.  The risk of suicidal thoughts and behavior should be carefully assessed against the risk of untreated illness, bearing in mind that epilepsy and many other conditions for which AEDs are prescribed are themselves associated with morbidity and mortality and an increased risk of suicidal thoughts and behavior.  Patients, caregivers, and families should be alert to the emergence or worsening of signs and symptoms of depression, any unusual changes in mood or behavior, or the emergence of suicidal thoughts or behavior.  If patients have symptoms of suicidal ideation or behavior, a dosage reduction or treatment discontinuation should be considered.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (18285, 21305, 'Pregabalin', 'Depressive Disorder', 'Antiepileptic drugs (AEDs) have been associated with an increased risk of suicidal thoughts or behavior in patients taking these drugs for any indication.  Pooled analyses of 199 placebo-controlled clinical studies involving the use of 11 different AEDs showed that patients receiving AEDs had approximately twice the risk of suicidal thinking or behavior compared to patients receiving placebo.  AEDs should be administered cautiously in patients with depression or other psychiatric disorders.  The risk of suicidal thoughts and behavior should be carefully assessed against the risk of untreated illness, bearing in mind that epilepsy and many other conditions for which AEDs are prescribed are themselves associated with morbidity and mortality and an increased risk of suicidal thoughts and behavior.  Patients, caregivers, and families should be alert to the emergence or worsening of signs and symptoms of depression, any unusual changes in mood or behavior, or the emergence of suicidal thoughts or behavior.  If patients have symptoms of suicidal ideation or behavior, a dosage reduction or treatment discontinuation should be considered.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (18286, 21982, 'Pregabalin', 'Depressive Disorder', 'Antiepileptic drugs (AEDs) have been associated with an increased risk of suicidal thoughts or behavior in patients taking these drugs for any indication.  Pooled analyses of 199 placebo-controlled clinical studies involving the use of 11 different AEDs showed that patients receiving AEDs had approximately twice the risk of suicidal thinking or behavior compared to patients receiving placebo.  AEDs should be administered cautiously in patients with depression or other psychiatric disorders.  The risk of suicidal thoughts and behavior should be carefully assessed against the risk of untreated illness, bearing in mind that epilepsy and many other conditions for which AEDs are prescribed are themselves associated with morbidity and mortality and an increased risk of suicidal thoughts and behavior.  Patients, caregivers, and families should be alert to the emergence or worsening of signs and symptoms of depression, any unusual changes in mood or behavior, or the emergence of suicidal thoughts or behavior.  If patients have symptoms of suicidal ideation or behavior, a dosage reduction or treatment discontinuation should be considered.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (18287, 21983, 'Pregabalin', 'Depressive Disorder', 'Antiepileptic drugs (AEDs) have been associated with an increased risk of suicidal thoughts or behavior in patients taking these drugs for any indication.  Pooled analyses of 199 placebo-controlled clinical studies involving the use of 11 different AEDs showed that patients receiving AEDs had approximately twice the risk of suicidal thinking or behavior compared to patients receiving placebo.  AEDs should be administered cautiously in patients with depression or other psychiatric disorders.  The risk of suicidal thoughts and behavior should be carefully assessed against the risk of untreated illness, bearing in mind that epilepsy and many other conditions for which AEDs are prescribed are themselves associated with morbidity and mortality and an increased risk of suicidal thoughts and behavior.  Patients, caregivers, and families should be alert to the emergence or worsening of signs and symptoms of depression, any unusual changes in mood or behavior, or the emergence of suicidal thoughts or behavior.  If patients have symptoms of suicidal ideation or behavior, a dosage reduction or treatment discontinuation should be considered.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (18288, 22139, 'Pregabalin', 'Depressive Disorder', 'Antiepileptic drugs (AEDs) have been associated with an increased risk of suicidal thoughts or behavior in patients taking these drugs for any indication.  Pooled analyses of 199 placebo-controlled clinical studies involving the use of 11 different AEDs showed that patients receiving AEDs had approximately twice the risk of suicidal thinking or behavior compared to patients receiving placebo.  AEDs should be administered cautiously in patients with depression or other psychiatric disorders.  The risk of suicidal thoughts and behavior should be carefully assessed against the risk of untreated illness, bearing in mind that epilepsy and many other conditions for which AEDs are prescribed are themselves associated with morbidity and mortality and an increased risk of suicidal thoughts and behavior.  Patients, caregivers, and families should be alert to the emergence or worsening of signs and symptoms of depression, any unusual changes in mood or behavior, or the emergence of suicidal thoughts or behavior.  If patients have symptoms of suicidal ideation or behavior, a dosage reduction or treatment discontinuation should be considered.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (18289, 22143, 'Pregabalin', 'Depressive Disorder', 'Antiepileptic drugs (AEDs) have been associated with an increased risk of suicidal thoughts or behavior in patients taking these drugs for any indication.  Pooled analyses of 199 placebo-controlled clinical studies involving the use of 11 different AEDs showed that patients receiving AEDs had approximately twice the risk of suicidal thinking or behavior compared to patients receiving placebo.  AEDs should be administered cautiously in patients with depression or other psychiatric disorders.  The risk of suicidal thoughts and behavior should be carefully assessed against the risk of untreated illness, bearing in mind that epilepsy and many other conditions for which AEDs are prescribed are themselves associated with morbidity and mortality and an increased risk of suicidal thoughts and behavior.  Patients, caregivers, and families should be alert to the emergence or worsening of signs and symptoms of depression, any unusual changes in mood or behavior, or the emergence of suicidal thoughts or behavior.  If patients have symptoms of suicidal ideation or behavior, a dosage reduction or treatment discontinuation should be considered.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (18290, 22145, 'Pregabalin', 'Depressive Disorder', 'Antiepileptic drugs (AEDs) have been associated with an increased risk of suicidal thoughts or behavior in patients taking these drugs for any indication.  Pooled analyses of 199 placebo-controlled clinical studies involving the use of 11 different AEDs showed that patients receiving AEDs had approximately twice the risk of suicidal thinking or behavior compared to patients receiving placebo.  AEDs should be administered cautiously in patients with depression or other psychiatric disorders.  The risk of suicidal thoughts and behavior should be carefully assessed against the risk of untreated illness, bearing in mind that epilepsy and many other conditions for which AEDs are prescribed are themselves associated with morbidity and mortality and an increased risk of suicidal thoughts and behavior.  Patients, caregivers, and families should be alert to the emergence or worsening of signs and symptoms of depression, any unusual changes in mood or behavior, or the emergence of suicidal thoughts or behavior.  If patients have symptoms of suicidal ideation or behavior, a dosage reduction or treatment discontinuation should be considered.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (18291, 22146, 'Pregabalin', 'Depressive Disorder', 'Antiepileptic drugs (AEDs) have been associated with an increased risk of suicidal thoughts or behavior in patients taking these drugs for any indication.  Pooled analyses of 199 placebo-controlled clinical studies involving the use of 11 different AEDs showed that patients receiving AEDs had approximately twice the risk of suicidal thinking or behavior compared to patients receiving placebo.  AEDs should be administered cautiously in patients with depression or other psychiatric disorders.  The risk of suicidal thoughts and behavior should be carefully assessed against the risk of untreated illness, bearing in mind that epilepsy and many other conditions for which AEDs are prescribed are themselves associated with morbidity and mortality and an increased risk of suicidal thoughts and behavior.  Patients, caregivers, and families should be alert to the emergence or worsening of signs and symptoms of depression, any unusual changes in mood or behavior, or the emergence of suicidal thoughts or behavior.  If patients have symptoms of suicidal ideation or behavior, a dosage reduction or treatment discontinuation should be considered.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (18292, 22147, 'Pregabalin', 'Depressive Disorder', 'Antiepileptic drugs (AEDs) have been associated with an increased risk of suicidal thoughts or behavior in patients taking these drugs for any indication.  Pooled analyses of 199 placebo-controlled clinical studies involving the use of 11 different AEDs showed that patients receiving AEDs had approximately twice the risk of suicidal thinking or behavior compared to patients receiving placebo.  AEDs should be administered cautiously in patients with depression or other psychiatric disorders.  The risk of suicidal thoughts and behavior should be carefully assessed against the risk of untreated illness, bearing in mind that epilepsy and many other conditions for which AEDs are prescribed are themselves associated with morbidity and mortality and an increased risk of suicidal thoughts and behavior.  Patients, caregivers, and families should be alert to the emergence or worsening of signs and symptoms of depression, any unusual changes in mood or behavior, or the emergence of suicidal thoughts or behavior.  If patients have symptoms of suicidal ideation or behavior, a dosage reduction or treatment discontinuation should be considered.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (18293, 22148, 'Pregabalin', 'Depressive Disorder', 'Antiepileptic drugs (AEDs) have been associated with an increased risk of suicidal thoughts or behavior in patients taking these drugs for any indication.  Pooled analyses of 199 placebo-controlled clinical studies involving the use of 11 different AEDs showed that patients receiving AEDs had approximately twice the risk of suicidal thinking or behavior compared to patients receiving placebo.  AEDs should be administered cautiously in patients with depression or other psychiatric disorders.  The risk of suicidal thoughts and behavior should be carefully assessed against the risk of untreated illness, bearing in mind that epilepsy and many other conditions for which AEDs are prescribed are themselves associated with morbidity and mortality and an increased risk of suicidal thoughts and behavior.  Patients, caregivers, and families should be alert to the emergence or worsening of signs and symptoms of depression, any unusual changes in mood or behavior, or the emergence of suicidal thoughts or behavior.  If patients have symptoms of suicidal ideation or behavior, a dosage reduction or treatment discontinuation should be considered.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (18294, 22150, 'Pregabalin', 'Depressive Disorder', 'Antiepileptic drugs (AEDs) have been associated with an increased risk of suicidal thoughts or behavior in patients taking these drugs for any indication.  Pooled analyses of 199 placebo-controlled clinical studies involving the use of 11 different AEDs showed that patients receiving AEDs had approximately twice the risk of suicidal thinking or behavior compared to patients receiving placebo.  AEDs should be administered cautiously in patients with depression or other psychiatric disorders.  The risk of suicidal thoughts and behavior should be carefully assessed against the risk of untreated illness, bearing in mind that epilepsy and many other conditions for which AEDs are prescribed are themselves associated with morbidity and mortality and an increased risk of suicidal thoughts and behavior.  Patients, caregivers, and families should be alert to the emergence or worsening of signs and symptoms of depression, any unusual changes in mood or behavior, or the emergence of suicidal thoughts or behavior.  If patients have symptoms of suicidal ideation or behavior, a dosage reduction or treatment discontinuation should be considered.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (18295, 22154, 'Pregabalin', 'Depressive Disorder', 'Antiepileptic drugs (AEDs) have been associated with an increased risk of suicidal thoughts or behavior in patients taking these drugs for any indication.  Pooled analyses of 199 placebo-controlled clinical studies involving the use of 11 different AEDs showed that patients receiving AEDs had approximately twice the risk of suicidal thinking or behavior compared to patients receiving placebo.  AEDs should be administered cautiously in patients with depression or other psychiatric disorders.  The risk of suicidal thoughts and behavior should be carefully assessed against the risk of untreated illness, bearing in mind that epilepsy and many other conditions for which AEDs are prescribed are themselves associated with morbidity and mortality and an increased risk of suicidal thoughts and behavior.  Patients, caregivers, and families should be alert to the emergence or worsening of signs and symptoms of depression, any unusual changes in mood or behavior, or the emergence of suicidal thoughts or behavior.  If patients have symptoms of suicidal ideation or behavior, a dosage reduction or treatment discontinuation should be considered.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (18296, 23147, 'Pregabalin', 'Depressive Disorder', 'Antiepileptic drugs (AEDs) have been associated with an increased risk of suicidal thoughts or behavior in patients taking these drugs for any indication.  Pooled analyses of 199 placebo-controlled clinical studies involving the use of 11 different AEDs showed that patients receiving AEDs had approximately twice the risk of suicidal thinking or behavior compared to patients receiving placebo.  AEDs should be administered cautiously in patients with depression or other psychiatric disorders.  The risk of suicidal thoughts and behavior should be carefully assessed against the risk of untreated illness, bearing in mind that epilepsy and many other conditions for which AEDs are prescribed are themselves associated with morbidity and mortality and an increased risk of suicidal thoughts and behavior.  Patients, caregivers, and families should be alert to the emergence or worsening of signs and symptoms of depression, any unusual changes in mood or behavior, or the emergence of suicidal thoughts or behavior.  If patients have symptoms of suicidal ideation or behavior, a dosage reduction or treatment discontinuation should be considered.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (18297, 23148, 'Pregabalin', 'Depressive Disorder', 'Antiepileptic drugs (AEDs) have been associated with an increased risk of suicidal thoughts or behavior in patients taking these drugs for any indication.  Pooled analyses of 199 placebo-controlled clinical studies involving the use of 11 different AEDs showed that patients receiving AEDs had approximately twice the risk of suicidal thinking or behavior compared to patients receiving placebo.  AEDs should be administered cautiously in patients with depression or other psychiatric disorders.  The risk of suicidal thoughts and behavior should be carefully assessed against the risk of untreated illness, bearing in mind that epilepsy and many other conditions for which AEDs are prescribed are themselves associated with morbidity and mortality and an increased risk of suicidal thoughts and behavior.  Patients, caregivers, and families should be alert to the emergence or worsening of signs and symptoms of depression, any unusual changes in mood or behavior, or the emergence of suicidal thoughts or behavior.  If patients have symptoms of suicidal ideation or behavior, a dosage reduction or treatment discontinuation should be considered.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (18298, 23429, 'Pregabalin', 'Depressive Disorder', 'Antiepileptic drugs (AEDs) have been associated with an increased risk of suicidal thoughts or behavior in patients taking these drugs for any indication.  Pooled analyses of 199 placebo-controlled clinical studies involving the use of 11 different AEDs showed that patients receiving AEDs had approximately twice the risk of suicidal thinking or behavior compared to patients receiving placebo.  AEDs should be administered cautiously in patients with depression or other psychiatric disorders.  The risk of suicidal thoughts and behavior should be carefully assessed against the risk of untreated illness, bearing in mind that epilepsy and many other conditions for which AEDs are prescribed are themselves associated with morbidity and mortality and an increased risk of suicidal thoughts and behavior.  Patients, caregivers, and families should be alert to the emergence or worsening of signs and symptoms of depression, any unusual changes in mood or behavior, or the emergence of suicidal thoughts or behavior.  If patients have symptoms of suicidal ideation or behavior, a dosage reduction or treatment discontinuation should be considered.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (18299, 23431, 'Pregabalin', 'Depressive Disorder', 'Antiepileptic drugs (AEDs) have been associated with an increased risk of suicidal thoughts or behavior in patients taking these drugs for any indication.  Pooled analyses of 199 placebo-controlled clinical studies involving the use of 11 different AEDs showed that patients receiving AEDs had approximately twice the risk of suicidal thinking or behavior compared to patients receiving placebo.  AEDs should be administered cautiously in patients with depression or other psychiatric disorders.  The risk of suicidal thoughts and behavior should be carefully assessed against the risk of untreated illness, bearing in mind that epilepsy and many other conditions for which AEDs are prescribed are themselves associated with morbidity and mortality and an increased risk of suicidal thoughts and behavior.  Patients, caregivers, and families should be alert to the emergence or worsening of signs and symptoms of depression, any unusual changes in mood or behavior, or the emergence of suicidal thoughts or behavior.  If patients have symptoms of suicidal ideation or behavior, a dosage reduction or treatment discontinuation should be considered.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (18300, 23432, 'Pregabalin', 'Depressive Disorder', 'Antiepileptic drugs (AEDs) have been associated with an increased risk of suicidal thoughts or behavior in patients taking these drugs for any indication.  Pooled analyses of 199 placebo-controlled clinical studies involving the use of 11 different AEDs showed that patients receiving AEDs had approximately twice the risk of suicidal thinking or behavior compared to patients receiving placebo.  AEDs should be administered cautiously in patients with depression or other psychiatric disorders.  The risk of suicidal thoughts and behavior should be carefully assessed against the risk of untreated illness, bearing in mind that epilepsy and many other conditions for which AEDs are prescribed are themselves associated with morbidity and mortality and an increased risk of suicidal thoughts and behavior.  Patients, caregivers, and families should be alert to the emergence or worsening of signs and symptoms of depression, any unusual changes in mood or behavior, or the emergence of suicidal thoughts or behavior.  If patients have symptoms of suicidal ideation or behavior, a dosage reduction or treatment discontinuation should be considered.', '2', '', 'DDInter', 0);
